KB105

AXP000198.1 · Viral vector gene therapy

Platform
HSV-1 (replication-defective)
Targets
TGM1
Originator
Krystal Biotech
Sponsor
Krystal Biotech

Names

NameTypeSource
KB105preferred name, codecurator, press

Virus

Role
In vivo gene transfer
Family
Herpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
non replicating
Modifications
replication-defective, non-integrating HSV-1 backbone; TGM1 cassette
Transgenes
TGM1
Route
topical
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05735158Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)UnknownPhase 22023-032024-0315Autosomal Recessive Ichthyosis
NCT04047732Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)UnknownPhase 1/22019-08-272022-106TGM-1 Related Autosomal Recessive Congenital Ichthyosis

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 32976879Preclinical Evaluation of a Modified Herpes Simplex Virus Type 1 Vector Encoding Human TGM1 for the Treatment of Autosomal Recessive Congenital Ichthyosis.The Journal of investigative dermatology2021name in abstract: KB105

Notes

Topical replication-defective, non-integrating HSV-1 vector delivering functional human TGM1 for TGM1-deficient autosomal recessive congenital ichthyosis (lamellar ichthyosis); phase 1/2 first-in-human, placebo-controlled, 2e9 pfu per site. Current development status not established in this pass.

How to cite

KB105 (AXP000198.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000198.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.